Brii Biosciences (FRA:7SS) EBITDA Margin %: -379.43% (As of Dec. 2025)


FRA:7SS Brii Biosciences Ltd FRA:7SS
33 GF Score
Price €0.10
! 1 Warning Sign
View Full Analysis

What is Brii Biosciences EBITDA Margin %?

Brii Biosciences FRA:7SS -18.03% 33 EBITDA Margin % is -379.43% as of Dec. 2025. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Brii Biosciences ranks worse than 80.74% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Brii Biosciences's EBITDA for the six months ended in Dec. 2025 was €-8.56 Mil. Brii Biosciences's Revenue for the six months ended in Dec. 2025 was €2.26 Mil. Therefore, Brii Biosciences's EBITDA margin for the quarter that ended in Dec. 2025 was -379.43%.

Brii Biosciences  (FRA:7SS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Brii Biosciences EBITDA Margin % Related Terms

Brii Biosciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Brii Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brii Biosciences EBITDA Margin % Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 -914.12 -27,344.30 0.00 -1,152.66

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -379.43

FRA:7SS vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Brii Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brii Biosciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's EBITDA Margin % falls into.


FRA:7SS
33GF Score
Brii Biosciences Ltd FRA:7SS
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brii Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Brii Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-26.004/2.256
=-1,152.66 %

Brii Biosciences's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-8.56/2.256
=-379.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -379.43% mean?
Brii Biosciences (FRA:7SS) has a EBITDA Margin % of -379.43% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Brii Biosciences and its competitors. According to the industry distribution chart, Brii Biosciences ranks #763 out of 945 companies in the Biotechnology industry, placing it in the top 80.7%.
Is Brii Biosciences' EBITDA Margin % too high?
Brii Biosciences' current EBITDA Margin % is -379.43%. Based on the distribution chart, Brii Biosciences ranks #763 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #763 out of 945 companies for EBITDA Margin %. This places Brii Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Brii Biosciences and its competitors. Brii Biosciences's current EBITDA Margin % is -379.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current EBITDA Margin % of -379.43%. The current EBITDA Margin % is -379.43%. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current EBITDA Margin % is -379.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brii Biosciences Business Description

Address No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score

Get the complete analysis for FRA:7SS

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price